immunity News and Research

RSS

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna).

From Calluna Pharma 24 Jan 2024

Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation

Researchers explore inflammatory signatures restricted to patients with active post-acute COVID-19 sequelae.

23 Jan 2024

Effects of varying COVID-19 vaccination rates on population-level health outcomes across variant waves in the U.S.

23 Jan 2024

From gut to brain: How diet can influence Alzheimer's and Parkinson's outcomes

Diet modification and alterations in the intestinal microbial population could impact the disease course of Alzheimer’s and Parkinson’s diseases.

23 Jan 2024

Microgravity may make space veggies more prone to bacteria

Lettuce and other leafy green vegetables are part of a healthy, balanced diet -; even for astronauts on a mission.

22 Jan 2024

Study reveals surprising power of CD4+ T cells against melanoma

In the study led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and published in Science Immunology, the researchers found that CD4+ T cells, traditionally called ‘helper T cells’ for their role in aiding the activation of other immune cells, are remarkably effective in controlling melanoma.

22 Jan 2024

COST Action bridges the gap in cancer immunotherapy research

Cancer is still a leading cause of death worldwide. Globally, there were an estimated 20 million new cases of cancer and 10 million deaths.

20 Jan 2024

Immune checkpoint inhibitor target found to promote skin cancer growth

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer.

19 Jan 2024

Montana’s effort to expand religious exemptions to vaccines prompts political standoff

Montana lawmakers are in a standoff with the state's health department over a package of sweeping changes to child care licensing rules that includes a disputed provision to allow religious exemptions to routine vaccinations for children and workers.

19 Jan 2024

CRISPR off-switch discovered: Safer gene editing for future therapies

Using CRISPR, an immune system bacteria use to protect themselves from viruses, scientists have harnessed the power to edit genetic information within cells.

19 Jan 2024

Memory T cells learn and adapt: Post-Omicron immunity offers wider protection

It has been 4 years since the start of the COVID-19 pandemic. SARS-CoV-2 has yet to be eradicated and new variants are continuously emerging.

19 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Bacteria's "suicidal" immune system boosts antibiotic power against cholera

Bacteria have an immune system that protects them against viruses known as bacteriophages. A research team from the Universities of Tübingen and Würzburg has now shown how this immune system enhances the effect of specific antibiotics against the cholera pathogen Vibrio cholerae.

19 Jan 2024